Kindred Biosciences Inc. (KIN) 15.05 $KIN
Kindred Biosciences Announces First Quarter 2014 Financial Results and Completion of Enrollment in CereKin Pivotal Study
PR Newswire - Mon May 12, 3:01PM CDT
Kindred Biosciences, Inc. (NASDAQ: KIN) today announced financial results for the quarter ended March 31, 2014. In addition, Kindred Bio announced that it has completed enrollment in KB010, its pivotal study for CereKinTM (diacerein).
Kindred Bio to Announce First Quarter 2014 Financial Results on Monday, May 12th
PR Newswire - Tue May 06, 8:03AM CDT
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, announced today that it will release its first quarter 2014 financial results on May 12, 2014 after the market close. The Company will host a conference call at 4:30 p.m. Eastern Time that day.
3 Horrendous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sun Apr 13, 9:00AM CDT
Plenty of health-care stocks hit major headwinds this week. Few were blown away like these three, though. One of this week's major losers disappointed investors with mid-stage clinical results. Another had some big news that didn't seem to move...
'Mad Money' Lightning Round: I Love Ecolab
at The Street - Tue Apr 08, 5:00AM CDT
Cramer says Encana is going higher but he's lukewarm on Diana Shipping.
Jim Cramer's 'Mad Money' Recap: Where's the Rally?
at The Street - Mon Apr 07, 7:13PM CDT
Cramer says the economy may be getting better but the markets sure aren't showing it.
Kindred Bio to Present at Needham 13th Annual Healthcare Conference
PR Newswire - Fri Apr 04, 8:03AM CDT
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will present at Needham 13th Annual Healthcare Conference in New York City:
Weakness Seen in Kindred Biosciences (KIN): Stock Tumbles 9.0% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 7:48AM CDT
Kindred Biosciences, Inc. (KIN) saw a big move last session`,continuing the recent downtrend for KIN, as the stock is now down more than 28.0% in the past one-month time frame.
Kindred Bio Announces Pricing of Public Offering
PR Newswire - Thu Apr 03, 8:03AM CDT
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the pricing of its public offering of 3,000,0000 shares of its common stock at a public offering price of $18.00 per share, for a total offering amount of $54,000,000 before deducting underwriting discounts and commissions and estimated offering expenses payable by Kindred Bio, upsized from the previously announced public offering of $50,000,000. Kindred Bio has granted to the underwriters a 30-day option to purchase up to an additional 450,000 shares of its common stock at the public offering price. All of the shares are being offered by Kindred Bio.
Kindred Biosciences launches public offering of common stock
M2 - Tue Apr 01, 5:37AM CDT
US-based biopharmaceutical company Kindred Biosciences (NasdaqCM:KIN) reported on Monday that it expects to launch USD50m shares of its common stock in a public offering.
Kindred Bio Announces Launch of Public Offering
PR Newswire - Mon Mar 31, 3:09PM CDT
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the commencement of its public offering of approximately $50 million of shares of common stock pursuant to a registration statement on Form S-1 filed with the U.S. Securities and Exchange Commission. The number of shares to be offered and the public offering price have not yet been determined.
Kindred Bio and X-Body Announce an Exclusive Collaboration for Discovery of Antibodies for Companion Animal Health
PR Newswire - Mon Mar 31, 8:03AM CDT
Kindred Biosciences, Inc. (NASDAQ: KIN) and X-Body Biosciences (X-Body) jointly announced today an exclusive alliance in which X-Body will discover fully canine, feline, and equine antibodies for companion animal health, and Kindred Bio will develop and commercialize these antibodies. Kindred Bio will provide an upfront payment, research funding, milestones, and royalties, and X-Body will exclusively license these antibodies to Kindred Bio.
Kindred Bio Announces Initiation of Pivotal Clinical Study for SentiKin(TM) in Dogs
PR Newswire - Fri Mar 28, 8:03AM CDT
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has initiated the pivotal clinical trial for SentiKin (KIND-009) for post-operative pain in dogs.
Kindred Bio Appoints Dr. Blake Hawley as Chief Commercial Officer, Announces upcoming Inclusion in Russell 2000
PR Newswire - Mon Mar 24, 8:10AM CDT
Kindred Biosciences, Inc. (NASDAQ: KIN) announced today that it has appointed Blake Hawley, D.V.M., as its Chief Commercial Officer. Separately, it also announced that it expects to be added to several Russell indexes on March 31, 2014.
Kindred Biosciences plans to issue common stock in public offering
M2 - Wed Mar 19, 7:21AM CDT
US-based biopharmaceutical company Kindred Biosciences (NasdaqCM:KIN) said on Tuesday that it intends to launch a follow-on public offering of its common stock.
Kindred Bio Announces Proposed Public Offering
PR Newswire - Tue Mar 18, 4:09PM CDT
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission for a proposed follow-on public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined.
Kindred Biosciences Announces Fourth Quarter and Year End 2013 Financial Results
PR Newswire - Thu Mar 06, 7:00AM CST
Kindred Biosciences, Inc. (NASDAQ: KIN) today announced financial results for the fourth quarter and year ended December 31, 2013. Kindred Bio will host a webcast and conference call at 1:30 p.m. (PT) this afternoon to review its corporate progress and financial results.
Kindred Bio to Present at Roth Capital Partners 26th Annual Growth Stock Conference
PR Newswire - Tue Mar 04, 9:24AM CST
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will present at Roth Capital Partners 26th Annual Growth Stock Conference in Dana Point, CA:
Kindred Bio to Announce Fourth Quarter and Year-End Financial Results on Thursday, March 6th
PR Newswire - Thu Feb 27, 8:10AM CST
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, announced today that it will release its 2013 fourth quarter and year-end financial results on March 6, 2014 after the market closes. The Company will host a conference call at 4:30 p.m. Eastern Time that day.
Kindred Bio begins second pivotal clinical study of AtoKin in dogs
M2 - Fri Feb 21, 4:46AM CST
US-based biopharmaceutical company Kindred Biosciences (NasdaqCM:KIN) reported on Thursday the start of its second pivotal clinical trial of AtoKin (KIND-002) in dogs with atopic dermatitis.
Kindred Bio Announces Initiation of Pivotal Clinical Study for AtoKin(TM) in Dogs
PR Newswire - Thu Feb 20, 8:10AM CST
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has initiated a pivotal clinical trial for AtoKin (KIND-002) in dogs with atopic dermatitis. The trial is being conducted at veterinary sites across the United States and, if positive, is expected to lead to the approval of AtoKin by 2015.
Kindred Biosciences Announces First Quarter 2014 Financial Results and Completion of Enrollment in CereKin Pivotal Study
PR Newswire - Mon May 12, 3:01PM CDT
Kindred Biosciences, Inc. (NASDAQ: KIN) today announced financial results for the quarter ended March 31, 2014. In addition, Kindred Bio announced that it has completed enrollment in KB010, its pivotal study for CereKinTM (diacerein).
Kindred Bio to Announce First Quarter 2014 Financial Results on Monday, May 12th
PR Newswire - Tue May 06, 8:03AM CDT
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, announced today that it will release its first quarter 2014 financial results on May 12, 2014 after the market close. The Company will host a conference call at 4:30 p.m. Eastern Time that day.
3 Horrendous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sun Apr 13, 9:00AM CDT
Plenty of health-care stocks hit major headwinds this week. Few were blown away like these three, though. One of this week's major losers disappointed investors with mid-stage clinical results. Another had some big news that didn't seem to move...
'Mad Money' Lightning Round: I Love Ecolab
at The Street - Tue Apr 08, 5:00AM CDT
Cramer says Encana is going higher but he's lukewarm on Diana Shipping.
Jim Cramer's 'Mad Money' Recap: Where's the Rally?
at The Street - Mon Apr 07, 7:13PM CDT
Cramer says the economy may be getting better but the markets sure aren't showing it.
Kindred Bio to Present at Needham 13th Annual Healthcare Conference
PR Newswire - Fri Apr 04, 8:03AM CDT
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will present at Needham 13th Annual Healthcare Conference in New York City:
Weakness Seen in Kindred Biosciences (KIN): Stock Tumbles 9.0% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 7:48AM CDT
Kindred Biosciences, Inc. (KIN) saw a big move last session`,continuing the recent downtrend for KIN, as the stock is now down more than 28.0% in the past one-month time frame.
Kindred Bio Announces Pricing of Public Offering
PR Newswire - Thu Apr 03, 8:03AM CDT
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the pricing of its public offering of 3,000,0000 shares of its common stock at a public offering price of $18.00 per share, for a total offering amount of $54,000,000 before deducting underwriting discounts and commissions and estimated offering expenses payable by Kindred Bio, upsized from the previously announced public offering of $50,000,000. Kindred Bio has granted to the underwriters a 30-day option to purchase up to an additional 450,000 shares of its common stock at the public offering price. All of the shares are being offered by Kindred Bio.
Kindred Biosciences launches public offering of common stock
M2 - Tue Apr 01, 5:37AM CDT
US-based biopharmaceutical company Kindred Biosciences (NasdaqCM:KIN) reported on Monday that it expects to launch USD50m shares of its common stock in a public offering.
Kindred Bio Announces Launch of Public Offering
PR Newswire - Mon Mar 31, 3:09PM CDT
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the commencement of its public offering of approximately $50 million of shares of common stock pursuant to a registration statement on Form S-1 filed with the U.S. Securities and Exchange Commission. The number of shares to be offered and the public offering price have not yet been determined.
Kindred Bio and X-Body Announce an Exclusive Collaboration for Discovery of Antibodies for Companion Animal Health
PR Newswire - Mon Mar 31, 8:03AM CDT
Kindred Biosciences, Inc. (NASDAQ: KIN) and X-Body Biosciences (X-Body) jointly announced today an exclusive alliance in which X-Body will discover fully canine, feline, and equine antibodies for companion animal health, and Kindred Bio will develop and commercialize these antibodies. Kindred Bio will provide an upfront payment, research funding, milestones, and royalties, and X-Body will exclusively license these antibodies to Kindred Bio.
Kindred Bio Announces Initiation of Pivotal Clinical Study for SentiKin(TM) in Dogs
PR Newswire - Fri Mar 28, 8:03AM CDT
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has initiated the pivotal clinical trial for SentiKin (KIND-009) for post-operative pain in dogs.
Kindred Bio Appoints Dr. Blake Hawley as Chief Commercial Officer, Announces upcoming Inclusion in Russell 2000
PR Newswire - Mon Mar 24, 8:10AM CDT
Kindred Biosciences, Inc. (NASDAQ: KIN) announced today that it has appointed Blake Hawley, D.V.M., as its Chief Commercial Officer. Separately, it also announced that it expects to be added to several Russell indexes on March 31, 2014.
Kindred Biosciences plans to issue common stock in public offering
M2 - Wed Mar 19, 7:21AM CDT
US-based biopharmaceutical company Kindred Biosciences (NasdaqCM:KIN) said on Tuesday that it intends to launch a follow-on public offering of its common stock.
Kindred Bio Announces Proposed Public Offering
PR Newswire - Tue Mar 18, 4:09PM CDT
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission for a proposed follow-on public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined.
Kindred Biosciences Announces Fourth Quarter and Year End 2013 Financial Results
PR Newswire - Thu Mar 06, 7:00AM CST
Kindred Biosciences, Inc. (NASDAQ: KIN) today announced financial results for the fourth quarter and year ended December 31, 2013. Kindred Bio will host a webcast and conference call at 1:30 p.m. (PT) this afternoon to review its corporate progress and financial results.
Kindred Bio to Present at Roth Capital Partners 26th Annual Growth Stock Conference
PR Newswire - Tue Mar 04, 9:24AM CST
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will present at Roth Capital Partners 26th Annual Growth Stock Conference in Dana Point, CA:
Kindred Bio to Announce Fourth Quarter and Year-End Financial Results on Thursday, March 6th
PR Newswire - Thu Feb 27, 8:10AM CST
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, announced today that it will release its 2013 fourth quarter and year-end financial results on March 6, 2014 after the market closes. The Company will host a conference call at 4:30 p.m. Eastern Time that day.
Kindred Bio begins second pivotal clinical study of AtoKin in dogs
M2 - Fri Feb 21, 4:46AM CST
US-based biopharmaceutical company Kindred Biosciences (NasdaqCM:KIN) reported on Thursday the start of its second pivotal clinical trial of AtoKin (KIND-002) in dogs with atopic dermatitis.
Kindred Bio Announces Initiation of Pivotal Clinical Study for AtoKin(TM) in Dogs
PR Newswire - Thu Feb 20, 8:10AM CST
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has initiated a pivotal clinical trial for AtoKin (KIND-002) in dogs with atopic dermatitis. The trial is being conducted at veterinary sites across the United States and, if positive, is expected to lead to the approval of AtoKin by 2015.
